IPT defines maiden Lake Hope measured resource
Impact Minerals expects to complete the pre-feasibility study for its Lake Hope high purity alumina project in Q1 2025
Stockhead
Neurizon’s lead drug confirms ALS treatment potential
Positive results of preclinical studies confirm the potential of Neurizon’s lead drug candidate NUZ-001 to be a transformative treatment for Amyotrophic Lateral Sclerosis (ALS).
Can Echo IQ keep things pumping?
With FDA approval in the bag for its AI-based aortic stenosis diagnostic tool, Echo IQ is focused on commercialisation over the next few years.
GT1 MD discusses ongoing drilling
Sarah Hughan sits down with Green Technology Metals’ MD, Cameron Henry, to discuss drilling at the Root lithium project in Ontario, Canada, and its potential to support a resource upgrade.
More Stories
Lunch Wrap: ASX up as Selfwealth gains suitor
The ASX has risen on Thursday, thanks to positive US inflation news. Meanwhile, Xero has ticked up 5 per cent and Selfwealth has attracted off a second suitor.
Archer Materials seems to be back on target
Collette Capital’s Steve Collette says interest is returning in semiconductor stock Archer Materials, which is eyeing new resistance levels after a mid-year slump.
GTI to update Lo Herma resource by year-end
GTI Energy is on track to update its Lo Herma uranium resource and exploration target by the end of 2024 and is moving to expand its footprint.
Imricor eyes worldwide expansion with progress on US and EU regulatory approval
Imricor Medical Systems is racing through regulatory initiatives supporting new device approvals in the US and Europe with the US Food and Drug Administration (FDA) completing a review of its first premarket approval (PME) module ahead of schedule.
Explorers Podcast: Future Battery Minerals
Barry FitzGerald chats with Future Battery Minerals’ Nick Rathjen to talk positioning for the future on a compelling Coolgardie lithium play.
Pharma/chemist union turns heads
Morgans healthcare analyst Scott Power had his eyes on Sigma Healthcare this week, which soared after the ACCC approves its merger with Chemist Warehouse.
Actinogen ‘on track’ with Alzheimer’s trial
ASX stock Actinogen reports its advanced – and novel – Alzheimer’s disease trial is recruiting strongly, with first results expected by mid next year.
Orthocell’s John Van Der Wielen chats US nerve repair sector
Orthocell’s chairman John Van Der Wielen joins Sarah Hughan on Stockhead TV to talk about the company’s commercial plans for its Remplir product in the US.
Far East Gold’s initial inferred Idenburg estimate
Stockhead TV brings you today’s Break it Down, detailing the initial inferred resource estimate from Far East Gold’s Indonesian Idenburg project.
Arika flags gold potential at depth in WA
Arika Resources says a data review of its Yundamindra gold project in WA highlights depth and strike potential.
Original URL: https://www.goldcoastbulletin.com.au/business/stockhead/page/7